Revolutionary Dehydration Technology

Global research collaborator with Nestlé SA,Danisco AS, Grupo Bimbo SA & Grimmway Farms

CompanyRadiant Energy Vacuum (“REV”) Dehydration Technology

Vancouver-based industrial technology company, UBC spin-offNew proprietary method of drying food, bulk liquids, biological and pharmaceutical material Large, diverse global markets use drying to extend shelf-life, reduce shipping & storage costs, create novel productsMission is to introduce a new global dehydration platform to compete with freeze drying, air drying & spray drying

REV Technology PlatformsPositioned to Compete in Broad Market Segments

Platform Functionality Markets

nutraREV™ Dehydrates pieces of solid food; continuous tumble drying

Low-fat snacksNutraceuticals

Pet & Baby food

Functional foodsDried fruits, vegetables,

herbs meats

powderREV™ Converts bulk frozen material to dry powder; accelerated, continuous freeze drying

Probiotics Food cultures

Proteins

EnzymesBulk food

Pharmaceuticals

quantaREV™ Dries pastes, gels, liquids, or particulates; continuous high-volume belt drying above freezing

Bulk FoodFruit PomaceConcentratesIngredients

Protein suspensionsEnzymes

PharmaceuticalsEncapsulated materials

bioREV™/freezeREV™

High-speed continuous dehydration of biomaterials in vials

VaccinesAntibodies

Other injectable drugs

Non-regulated biologicals and reagents

MIVAP™ High-speed, low temperature drying of purees in trays

Meat pureesFruit slices

PomaceEncapsulated enzymes

Commercial Progression

REV TechnologyPatents filed,

issued or pending

Conceptual prototype

stage

Pilot development

stage

Commercial development

stage (1)

Multi-national collaboration

partners

Regulatory approval

anticipated (3)

nutraREV™ Nestlé & Bimbo N/A

powderREV™ 9 to 12 months (2) Danisco N/A

quantaREV™ 12 to 18months Grimmway N/A

freezeREV™ 3+ years TBD Yes

bioREV™ TBD TBD Yes

(1) Commercial machine with dried capacity of up to 100 Kilo per hour sold to CAL-SAN, testing initiated with Nestlé & Bimbo in 2010(2) Expected time required to complete pilot machine testing, Danisco licence agreement and secure first commercial machine order for

delivery in first half of 2012(3) FDA GMP regulatory approvals required for therapeutic pharmaceutical applications

Technology Development Targets as of January 2011

Commercialization StrategyTwo tier approach for broader market acceptance

Strategic Plan: start with collaborations, build a royalty stream from technology licenses, outsource manufacturing of REV machines

Tier One:

Strategic collaborations with leading multinationals, exclusive agreements for specific global market segments, targeted annual royalties $25-$50M per divisionNestlé SA, Danisco AS, Grupo Bimbo SA & Grimmway Farms

Tier Two:

Entrepreneurial or regional partnerships with limited territory or product exclusivity, targeted annual royalties of $1-$5M per partnerCAL-SAN Enterprises, IFS/Smartpac

Intellectual Property StrategySupporting the Strategic Plan

ENW owns 7 patents/pending plus exclusive world-wide rights to 7 patents filed by UBC (Dr. Tim Durance): 2016 - 2024

IP protection strategy: patent in big markets where machines are likely to be installed, or product sales may occur - India, China, Brazil, EU and North America, possibly other countries depending on the application

PCT route gives 2 ½ years to decide where to file. Start with US provisional while invention is refined, then file PCT within 12 months.  ~ 4 months later, the PCT patent examiner conducts search and gives written opinion. National patent filings in selected countries 30 months after the provisional application.  Takes a further 1-5 years to obtain patents.

CollaborationsGive & Take with Tier 1 & Tier 2 Partners

Global collaborations help move us along the Technology Adoption Life Cycle* (innovators, early adopters, early majority, late majority, laggards):

Detailed knowledge of industry needs, “pain” and costs

Product & market expertise

Credibility with investment community to raise funds on public markets

Credibility with target markets where brand names sign on publicly

CollaborationsGive & Take with Tier 1 & Tier 2 Partners

Strong base of intellectual property

Exclusivity of testing for specific products/regions/timeframe

Public collaboration announcements

Investor confidence & increasing levels of financing

Cash for in-house technology development

Ownership of all IP

Grant exclusive licenses for royalties

Open InnovationLessons learned – the bad news first

Important to establish clear property rights before or at first meeting

Everything takes longer than you think, esp. with large companies

Smaller companies may not have the horsepower or experience needed

to bring products to market

Confidential agreement terms difficult for investors (but good for us)

Open InnovationLessons learned – now, the good news

Collaboration benefits:Farm out work to external facilities/experts to reduce costsThird party technology endorsementIncrease speed to market with internal champions at multinationalsAssistance with regulatory approval processHelp design best machine to meet industry needs (batch vs continuous, size, processing speed, necessary savings to justify investment)

So far, no regrets. Each collaboration has served a valuable purpose and we learn from every one.

Open InnovationSelected examples

Aridis Pharmaceuticals – Early credibility with investors, learned about sector, provided prototype design input, too small for larger collaboration

Danisco AS – First global collaboration, great partner, good credibility

Bioseutica PLC – Good signal to huge market in encapsulation

Nestlé SA – Best possible reference in food industry

SRC – Detailed feedback on design, help us keep costs low

Contact Details

www.enwave.net | TSX-V: ENW | FSE: E4U

Jennifer ThompsonV.P. Corporate Development & Investor Relations

P: (604) 603-6549E: jthompson@enwave.net